BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York

SAN RAFAEL, Calif., Oct. 1, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. BMRN today announced that Robert Baffi, Ph.D., President of Global Manufacturing and Technical Operations, will participate in a fireside discussion at the Jefferies Gene Therapy/Editing Summit on October 8, 2019 at 11:15am ET in New York.  Dr. Baffi will also participate in the panel discussion on manufacturing, dose, and durability in gene therapy at 10:20am ET, which will not be available by webcast.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

To access the live webcast presentation, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following each event.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of seven commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.

Contacts:



Investors 

Media

Traci McCarty 

Debra Charlesworth

BioMarin Pharmaceutical Inc. 

BioMarin Pharmaceutical Inc.

(415) 455-7558 

(415) 455-7451

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biomarin-to-participate-in-jefferies-gene-therapyediting-summit-on-october-8-2019-in-new-york-300928381.html

SOURCE BioMarin Pharmaceutical Inc.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releasestrade shows
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!